Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK2 | Q92630 | 14/20 | 0.74 |
| ▸ | CDK6 | Q00534 | 6/20 | 0.72 |
| ▸ | CDK4 | P11802 | 1/20 | 0.54 |
| ▸ | CCND1 | P24385 | 1/20 | 0.54 |
| ▸ | CCND3 | P30281 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26451650 | 1.00 | DYRK2 (0.74) | DYRK2CDK6CDK4CCND1CCND3 | |
| SCHEMBL26451247 | 0.93 | DYRK2 (0.76) | DYRK2CDK6CDK4CCND1CCND3 | |
| SCHEMBL30569708 | 0.93 | DYRK2 (0.76) | DYRK2CDK6CDK4CCND1CCND3 | |
| SCHEMBL26447972 | 0.91 | DYRK2 (0.79) | DYRK2CDK6CDK4CCND1CCND3 | |
| SCHEMBL26451835 | 0.90 | DYRK2 (0.71) | DYRK2CDK6CDK4CCND1CCND3 | |
| SCHEMBL26447989 | 0.88 | DYRK2 (0.79) | DYRK2CDK6CDK4CCND1 | |
| SCHEMBL26447977 | 0.88 | DYRK2 (0.78) | DYRK2CDK6CDK4CCND1 | |
| Hydrochloric Acid SCHEMBL26680009 | 0.87 | DYRK2 (0.80) | DYRK2CDK6CDK4CCND1 | |
| SCHEMBL32677355 | 0.86 | DYRK2 (0.70) | DYRK2CDK6 | |
| SCHEMBL26447987 | 0.86 | DYRK2 (0.70) | DYRK2CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559485-B2 | CDK6/DYRK2 dual-target inhibitor, and preparation method therefor and use thereof | JIANGSU TASLY DIYI PHARMACEUTICAL CO. , LTD. (CN) | 2026-02-24 | — | — | US | disclosed |
| EP-4282864-B1 | CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU TASLY DIYI PHARMACEUTICAL CO LTD (CN) | 2025-08-13 | — | — | EP | disclosed |
| EP-4282864-A1 | CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (CN) | 2023-11-29 | — | — | EP | disclosed |
| US-20230303553-A1 | CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303553-A1 | CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CDK6, DYRK2, CDK16 | DYRK2 2/4885CDK6 1/4885CDK4 27/4885 |
| US-12559485-B2 | CDK6/DYRK2 dual-target inhibitor, and preparation method therefor and use thereof | CDK6, CDK2, CDKL1 | DYRK2 23/4885CDK6 1/4885CDK4 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.